These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12831592)

  • 41. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome.
    Ozgun MT; Batukan C; Oner G; Uludag S; Aygen EM; Sahin Y
    Gynecol Endocrinol; 2008 Nov; 24(11):656-8. PubMed ID: 19031224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study.
    Salama KM; Abo Ragab HM; El Sherbiny MF; Morsi AA; Souidan II
    BMC Womens Health; 2017 Nov; 17(1):108. PubMed ID: 29132339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oocyte quality in patients with severe ovarian hyperstimulation syndrome: a self-controlled clinical study.
    Fábregues F; Peñarrubia J; Vidal E; Casals G; Vanrell JA; Balasch J
    Fertil Steril; 2004 Oct; 82(4):827-33. PubMed ID: 15482755
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos.
    Endo T; Honnma H; Hayashi T; Chida M; Yamazaki K; Kitajima Y; Azumaguchi A; Kamiya H; Kudo R
    Hum Reprod; 2002 Oct; 17(10):2548-51. PubMed ID: 12351526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ovarian hyperstimulation syndrome: A review for emergency clinicians.
    Timmons D; Montrief T; Koyfman A; Long B
    Am J Emerg Med; 2019 Aug; 37(8):1577-1584. PubMed ID: 31097257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ovarian hyperstimulation syndrome: definition, incidence, and classification.
    Zivi E; Simon A; Laufer N
    Semin Reprod Med; 2010 Nov; 28(6):441-7. PubMed ID: 21082501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimal monitoring of ovarian hyperstimulation: a useful simplification of the clinical phase of in vitro fertilization treatment.
    Roest J; Verhoeff A; van Heusden AM; Zeilmaker GH
    Fertil Steril; 1995 Sep; 64(3):552-6. PubMed ID: 7641909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
    Fábregues F; Tàssies D; Reverter JC; Carmona F; Ordinas A; Balasch J
    Fertil Steril; 2004 Apr; 81(4):989-95. PubMed ID: 15066453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries.
    Rimington MR; Walker SM; Shaw RW
    Hum Reprod; 1997 Jul; 12(7):1443-7. PubMed ID: 9262275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in ovarian hyperstimulation syndrome hospitalization rates in the USA: an ongoing concern.
    Rotshenker-Olshinka K; Badeghiesh A; Volodarsky-Perel A; Steiner N; Suarthana E; Dahan MH
    Reprod Biomed Online; 2020 Sep; 41(3):357-360. PubMed ID: 32693992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation.
    Danninger B; Brunner M; Obruca A; Feichtinger W
    Hum Reprod; 1996 Aug; 11(8):1597-9. PubMed ID: 8921098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can quantitative three-dimensional power Doppler angiography be used to predict ovarian hyperstimulation syndrome?
    Jayaprakasan K; Jayaprakasan R; Al-Hasie HA; Clewes JS; Campbell BK; Johnson IR; Raine-Fenning NJ
    Ultrasound Obstet Gynecol; 2009 May; 33(5):583-91. PubMed ID: 19402100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The number of oocytes retrieved during IVF: a balance between efficacy and safety.
    Magnusson Å; Källen K; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2018 Jan; 33(1):58-64. PubMed ID: 29136154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ovarian stimulation in patients in risk of OHSS.
    Soave I; Marci R
    Minerva Ginecol; 2014 Apr; 66(2):165-78. PubMed ID: 24848075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model.
    Ashrafi M; Bahmanabadi A; Akhond MR; Arabipoor A
    Arch Gynecol Obstet; 2015 Nov; 292(5):1145-52. PubMed ID: 25920524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome.
    Korhonen KV; Savolainen-Peltonen HM; Mikkola TS; Tiitinen AE; Unkila-Kallio LS
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():162-168. PubMed ID: 27865939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.